Sense Raises $50M Series B To Accelerate Launch Of Covid-19 Molecular Test On Its Veros™ Instrument-Free Product Platform
Sense Raises $50M Series B To Accelerate Launch Of Covid-19 Molecular Test On Its Veros™ Instrument-Free Product Platform
04/20/21, 6:07 AM
Location
san franciscoMoney raised
$50 million
Round Type
series b
Sense Biodetection (Sense), today announced that it has raised a $50m Series B investment to advance commercialization of its VerosTM COVID-19 product and continue development of a portfolio of instrument-free, rapid molecular tests that enable improved access, outcomes, and value through patient-focused decentralized healthcare. The VerosTM platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. The Series B round was led by Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, Inc.
Company Info
Location
san francisco, california, united states
Additional Info
Through this personalized approach, its customers experience on average a 263% increase in candidates screened, compared to a manual approach, the company said. Sense, which has expanded into the Indian market, will use the funding to add new products, expand its team and go into newer geographies.